3 Healthcare Stocks That Have Held Up in Every Market Downturn

The article highlights Johnson & Johnson, Abbott Laboratories, and Becton, Dickinson as defensive healthcare names that have historically outperformed during recessions and all qualify as Dividend Kings. J&J reported 2025 trailing net profit margin of 28.5% and guided 2026 revenue to $99.5 billion-$100.5 billion, while Abbott posted 2025 sales of $44.3 billion and guided 2026 EPS of $5.55-$5.80; Becton reported first-quarter 2026 revenue of $5.3 billion and EPS of $1.34. The outlook is constructive but tempered by ongoing litigation and regulatory risks across all three companies.

Analysis

The market is increasingly paying up for balance-sheet durability, but the more important second-order effect is that recession-resilient healthcare is becoming a crowded parking place for capital whenever macro volatility spikes. That tends to compress forward multiple dispersion within the group: the lowest-quality legal/risk overhangs are discounted less aggressively than they should be, while the cleanest balance sheets can still rerate on defensive flows alone. In that setup, relative winners are the companies with the best free-cash-flow conversion and the smallest exposure to reimbursement shock, because they can keep compounding while peers de-rate.

The legal headlines matter more for timing than for terminal value. For JNJ and ABT, the market likely already knows the litigation cloud, but the next leg is driven by whether reserve additions or adverse judgments force a near-term capital allocation reset over the next 1-4 quarters. BDX is the cleanest quality franchise operationally, yet the FDA scrutiny creates a classic “slow burn” risk: not a demand collapse, but an overhang on multiple expansion until regulatory closure becomes visible.

The contrarian read is that “defensive” may be too simplistic here. If growth rolls over, these names can outperform on a relative basis, but they are not hedge assets; they can still fall in absolute terms if the market re-rates bond proxies or if litigation costs start to look less manageable. The best setup is not a blanket long, but a selective long/short where the market is overpaying for headline safety and underpricing legal drag or underappreciating the earnings durability of the cleanest operator.

Key Decisions for Investors

• Long JNJ vs short XLP on a 3-6 month horizon: JNJ has better operating leverage and dividend support than consumer staples if macro weakens, but downside is capped by more durable earnings and pipeline visibility. Target 8-12% relative outperformance; stop if litigation headlines force reserve escalation.
• Pair long ABT / short KVUE for 6-12 months: ABT has multiple self-help levers and diversified operating mix, while KVUE is the cleaner way to express litigation/consumer-health fragility without taking on broader healthcare beta. Use a 1:1 dollar-neutral structure.
• Delay new longs in BDX until regulatory noise improves; if it sells off on FDA headlines, buy weakness only if the stock de-rates 5-8% on no new operational impairment. Expect a 12-18 month holding period for full multiple recovery.
• For income accounts, scale into JNJ and ABT on market pullbacks rather than chasing strength; defensive flows can create entry points of 3-5% that improve dividend-adjusted returns meaningfully over 12 months.
• Avoid outright shorting any of the three unless litigation accelerates materially; the better risk/reward is relative-value short exposure versus lower-quality defensive healthcare names with weaker recurring revenue and no comparable dividend floor.